Analysis
Post-IPO stocks had one of their more volatile weeks of the summer. Caris Life Sciences (CAI) jumped 21.58% after reporting record second-quarter revenue of $263.7 million, up 45% year over year, and raising full-year guidance to $1.03-$1.04 billion -- the sharpest earnings reaction since the diagnostics company went public, according to Investing.com. Elsewhere in the index, Unity gained 35.6%, CoreWeave rose 26.3%, and Coherent climbed 40.7% on the FCC's proposed optical-transceiver import restriction.
Not every recent debut shared in the gains. BillionToOne, the diagnostics company that IPO'd earlier this year, fell 29.8% even after beating both revenue and EPS estimates -- 64% year-over-year revenue growth to $109.4 million and EPS of $0.15 against a $0.03 estimate -- because it reiterated rather than raised full-year guidance of $450-465 million. Medline slid 10.3% over the same stretch.
The split says something specific about where post-IPO investor patience currently sits: a beat alone isn't enough anymore if the company doesn't also raise the outlook, while a beat-and-raise like Caris's gets rewarded aggressively. For any company eyeing an IPO later this year, the read is straightforward -- price in room to raise guidance at the first quarterly report, because the market is actively punishing companies that merely meet a bar they've already cleared.
